Objective: Antenatal steroid use has been associated with reduction in the risk of neonatal mortality in meta-analyses of clinical trials. In 2007, a revised US birth certificate offered information on antenatal steroid use in 22 states. The aim of this study was to review the association between antenatal steroid use and neonatal mortality by gestational age categories for preterm infants (<37 weeks) for the United States for the year 2007. Result: There were 245 453 preterm births and 4220 neonatal deaths available for analysis with complete data on antenatal steroid use. The highest prevalence for antenatal steroid use among neonatal intensive care unit admissions (NICU) was 22% in the 26 to 28 week gestational age category, whereas the lowest prevalence was in the 34-to 36-week group at 7%. Following adjustment for potentially confounding variables by logistic regression, the adjusted odds ratios (95% confidence interval) for neonatal mortality (antenatal steroid use versus non-use) ranged from 0.56 (0.46 to 0.67) at 22 to 25 weeks; 0.66 (0.53 to 0.83) at 26 to 28 weeks; 0.69 (0.55 to 0.85) at 29 to 33 weeks and 0.69 (0.47 to 1.01) at 34 to 36 weeks.
Introduction

Antenatal steroid use and neonatal outcome: United States 2007
Antenatal steroid use for the maturation of fetal lung has become a standard of care endorsed and promoted by several national entities. 1, 2 The basis for these recommendations come from a series of trials performed between 1972 and 1990. These trials averaged around 100 women per trial randomized to a treatment, or placebo or non-treatment arm of the study. 3 Two large trials, Liggins 1972 and the Collaborative Trial (US) 1981, however, contributed large numbers of enrollees, 1142 and 696, respectively, and thus provide major influences on the perceived benefits of antenatal steroids. 4, 5 The most recent Cochrane review of 21 of these studies concludes, 'that treatment with antenatal corticosteroids reduces neonatal death, respiratory distress syndrome (RDS) and cerebroventricular hemorrhage in preterm infants'. 3 In subgroup analyses, the benefit to the reduction in neonatal death extended to infants at 26 to 29.9 weeks. Nevertheless, among these 21 studies, the number of infants born at <28 weeks gestation was only 129 with a calculated risk ratio of neonatal death of 0.81 (95% confidence interval (CI) ¼ 0.65 to 1.01).
Several observational studies have added information concerning the impact of antenatal steroid use among extremely preterm infants at 22 to 25 weeks and have reported significant reductions in mortality associated with the use of steroids. 6, 7 In contrast, a Norwegian population-based cohort study found no significant effect of antenatal steroids on reducing mortality. 8 A regional population-based study in England reported a significant reduction in mortality among infants delivered at 24 to 29 weeks gestation, but no significant reduction in mortality at <24 weeks. 9 In the United States, neonatal network-based observational studies have documented increasing use of antenatal steroids and a reduction in mortality among infants whose mothers received antenatal steroids. 10 It has only become possible to examine the relationship between antenatal steroid use and neonatal mortality in the US vital statistics data since the introduction of the 2003 birth certificate. A number of maternal demographic, pregnancy, labor and delivery characteristics, and infant birth characteristics were extracted from the downloaded files. The analysis was limited to infants 22 to 36 weeks gestation and to only those records with information on the use of antenatal steroids. There was no information available concerning the timing or the number of doses of antenatal steroids that mothers may have received. Information on the age and cause of death was extracted from linked death certificates.
Analyses were done using SAS (Cary, NC, USA). The w 2 analyses were used for determining statistical significance for nominal variables and t-tests for continuous variable comparisons. Multivariate logistic regression modeling was used to determine the strength of association between neonatal outcomes and antenatal steroid use controlling for potentially confounding variables. An arbitrary P-value of <0.05 was designated as statistically significant.
Results
There were 245 453 live births from 22 to 36 weeks of gestation available for analysis and 4220 neonatal deaths that had information available from the states reporting antenatal steroid use. Women receiving antenatal steroids were more likely to be older (>35 years), have more years of education, be of white race, be in their first pregnancy and to be delivered by cesarean section (Table 1) . Infants born to mothers receiving antenatal steroids were more likely to weigh less, to have been admitted to a neonatal intensive care unit (NICU), to have been received surfactant and to have receive mechanical ventilation for >6 h ( Table 1 ). The distribution of the age of death for infants of mothers who received antenatal steroids was skewed to the right with many fewer deaths occurring in the first hour of life and more after the first week (Table 1) .
There was a significant interaction between antenatal steroid use and gestational age category, and between admission to the NICU and antenatal steroid use. Thus, analyses were stratified by gestational age and NICU admission. The overall prevalence of antenatal steroid exposure for infants admitted to the NICU was 14% compared with 2% for those not admitted to an NICU ( Table 2 ). The prevalence of antenatal steroid exposure for infants admitted to the NICU by gestational age categories of 22 to 25 weeks, 26 to 28 weeks, 29 to 33 weeks and 34 to 36 weeks was 20, 22, 20 and 7%, respectively ( Table 2 ).
The neonatal mortality rate was significantly reduced when all births were examined only for those infants born at 22 to 25 weeks gestation that received antenatal steroids compared with those not receiving steroids (rate ratio ¼ 0.62), Table 3 . When only those infants admitted to a NICU were examined, all the rate ratios were <1.0 at each gestational age category, indicating a protective effect of antenatal steroids except for the late preterm births, 34 to 36 weeks gestation (Table 3) . Although the point estimate for the late preterm births was reduced (0.76), the reduction did not attain statistical significance (P ¼ 0.25).
When all births were considered, following adjustment for a number of potentially confounding variables by logistic regression modeling, statistically significant reductions in neonatal mortality were observed for infants whose mothers received antenatal steroids at all gestational age categories except 34 to 36 weeks ( Table 4) . The late preterm birth-adjusted odds ratio, however, was comparably as low as the adjusted odds ratios of the other gestational age categories, but of marginal significance (0.69, 95% CI ¼ 0.47 to 1.01, P ¼ 0.057). When only NICU admissions were examined, the adjusted odds ratios were significantly reduced, suggesting a protective effect of antenatal steroid exposure for all gestational age categories except the 34-to 36-week group, which again attained a marginally significant reduction in the odds ratio (0.65, 95% CI ¼ 0.41 to 1.04, P ¼ 0.072) (Table 4) .
RDS, intraventricular hemorrhage (IVH) and necrotizing enterocolitis as specific causes of death were examined by antenatal steroid use. Because of the relatively small number of deaths attributed to these specific causes, the association with antenatal steroid use was examined over all births and gestational age categories. There were 246 neonatal deaths attributed to RDS, 211 attributed to IVH and 197 attributed to necrotizing enterocolitis. Following adjustment for all demographic and infant variables, including gestational age and NICU admission, the adjusted odds ratios (95% CI) were 0.62 (0.43 to 0.90) for RDS; 0.60 (0.40 to 0.89) for IVH and 0.75 (0.50 to 1.11) for necrotizing enterocolitis.
Discussion
This analysis of antenatal steroid use among women delivering preterm infants from the states reporting antenatal steroid use on their birth certificates is in agreement with observations made from clinical trials, meta-analyses of those clinical trials, network reports and regional population-based studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] That is, antenatal steroid use reduces neonatal mortality among preterm infants. This analysis adds information on the relationship between antenatal steroid use and neonatal mortality to previous work in that it provides a large number of births in the 22-to 25-week gestational age category (n ¼ 5751) that were not included in the early clinical trials. 3 The Epicure Study, a prospective cohort study of infants born from 20 to 25 weeks gestation conducted in 1995 in all 276 maternity units in the United Kingdom and the Republic of Ireland, did report a significant survival advantage among infants receiving antenatal steroids, n ¼ 800, OR adj ¼ 0.57, 95% CI 0.38 to 0.85. 6 The Neonatal Research Network of National Institute of Child Health and Human Develepment reported a similar impact of antenatal steroid use among infants 22 to 25 weeks gestation with an adjusted odds ratio for death of 0.55 (95% CI 0.45 to 0.66) for 3702 infants admitted for intensive care. 7 Carlos et al.
15 using 16 years of the National Institute of Child Health and Human Develepment Neonatal Network data (1993 to 2009) reported similarly an impressive protective effect of antenatal steroids among the most immature infants at 22 to 25 weeks gestation. The adjusted odds ratio for mortality among infants receiving antenatal steroids was 0.58 (0.52 to 0.65). A cohort study from Norway that included infants 22 to 27 weeks gestation failed to find a significant protective effect (OR ¼ 0.77, 95% CI 0.42 to 1.25). 8 The number of births in that study, however, was small, n ¼ 86, and probably accounted for the lack of power to demonstrate a significant effect. The regional study in England reported a significant effect of antenatal steroid exposure on mortality between 24 and 29 weeks, but failed to adjust for any potentially confounding variables such as method of delivery. Despite the failure of the Norway study and the regional England study to report significant effects of antenatal steroids on the most preterm infants, the National Institute of Child Health and Human Develepment Neonatal Network studies 7, 15 and the populationbased analysis of US vital statistics data reported here do suggest a significant protective effect of antenatal steroids on infants at the limit of viability from 22 to 25 weeks gestation. In addition, the consistency of the adjusted odds ratios reported in the Network studies (0.57-Tyson, 0.58-Carlos) and this population-based analysis for infants admitted to a NICU (0.57) point to the robustness of this observation. Additionally, this analysis provides information on late preterm births (34 to 36 weeks, n ¼ 178 565) that were not included in the clinical trials, network studies and population-based studies. On the basis of this information, it may be inferred that antenatal steroid use does have at least a marginally protective effect for late preterm infants (OR adjÀall admissions ¼ 0.69, 95% CI ¼ 0.47 to 1.01, P ¼ 0.057). The failure to attain statistical significance at P<0.05 level for this group probably relates to the lack of statistical power for this category, with a relatively small number of deaths among neonates whose mothers received antenatal steroids (29 among all admissions and 19 among NICU admissions). As late preterm This analysis is also in agreement with the Cochrane review that observed a reduction in the occurrence of RDS and cerebroventricular hemorrhage in the infants of women treated with antenatal steroids. 3 Although this analysis could not determine prevalence of these entities, deaths attributed to RDS and IVH were determined after adjustment for potentially confounding variables to be significantly reduced among infants exposed to antenatal steroids.
This population-based analysis also points to a number of issues about who may receive antenatal steroids in the United States. Although it cannot be inferred that the states submitting information on antenatal steroid use are representative of the entire United States, the demographic characteristics independent of antenatal steroid use reflect closely the population characteristics of women delivering preterm infants in the entire nation. 17 White, mature women (>35 years), women carrying more than one fetus and women having cesarean sections appear more likely to receive antenatal steroids. Of particular interest is the relatively small proportion of Hispanics that received antenatal steroids (18%) compared with their distribution in the no-antenatal steroid group (33%). The observation that the prevalence of antenatal steroid use was so much greater among NICU admissions probably speaks to the fact that infants admitted to a NICU, particularly at very early gestational ages, were infants to which a commitment to treatment had been made. 18 The higher prevalence of surfactant use and assisted ventilation use among infants in the antenatal steroid use also speaks to the issue of commitment to treat.
This analysis points to a major shortcoming in the reporting of antenatal steroid use on birth certificate data. The largest proportion of infants exposed to antenatal steroids was in the NICU admissions at 26 to 28 weeks gestation (22%). This is an exceptionally low proportion compared with what is reported in most network and population-based studies that range in the vicinity of 60 to 90% of infants admitted to NICUs at 22 to 28 weeks gestation. 7, 10 Why this underreporting should occur is uncertain. The effect of this possible underreporting of the use of antenatal steroids will, if anything, be to underestimate the protective effect of the steroids. This is a form of non-differential misclassification that results in the underestimation of the exposure effect. 19 Another major problem in using vital statistics data is the misclassification problems associated with the estimation of gestational age and the concurrence of birth weight for gestational age. 20, 21 In other analyses evaluating neonatal or infant mortality using vital statistics data efforts to correct for this problem have been made by removing records with birth weights deviating from set limits for estimated birth weights ranges for specific gestational ages. 22 In this analysis, birth weight was included as a continuous variable adjusted for within the logistic models run for the stratified gestational age categories. Nevertheless, the problem of misclassification for gestational age categories may still distort the results.
In summary, this population-based analysis of information from states reporting the use of antenatal steroids provides confirmatory evidence of the reduction of neonatal mortality with antenatal steroid use among women delivering preterm infants and even among infants at the limits of viability at 22 to 25 weeks gestation. The marginally positive impact of antenatal steroid use among late preterm infants (34 to 36 weeks gestation) observed in this analysis suggests that expanding the recommendation for the use of antenatal steroids to include this group of preterm infants may have merit.
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